Abstract
Nitric oxide is a pleiotropic ancestral molecule, which elicits beneficial effect in many physiological settings but is also tenaciously expressed in numerous pathological conditions, particularly breast tumors. Nitric oxide is particularly harmful in adipogenic milieu of the breast, where it initiates and promotes tumorigenesis. Epidemiological studies have associated populations at a greater risk for developing breast cancer, predominantly estrogen receptor positive tumors, to express specific polymorphic forms of endothelial nitric oxide synthase, that produce sustained low levels of nitric oxide. Low sustained nitric oxide generates oxidative stress and inflammatory conditions at susceptible sites in the heterogeneous microenvironment of the breast, where it promotes cancer related events in specific cell types. Inflammatory conditions also stimulate inducible nitric oxide synthase expression, which dependent on the microenvironment, could promote or inhibit mammary tumors. In this review we re-examine the mechanisms by which nitric oxide promotes initiation and progression of breast cancer and address some of the controversies in the field.
Keywords: Breast cancer, oxidative stress, estrogen, angiogenesis, inflammation, nitric oxide, proliferation
Current Pharmaceutical Design
Title: NO to Breast: When, Why and Why Not?
Volume: 16 Issue: 4
Author(s): Shehla Pervin, Gautam Chaudhuri and Rajan Singh
Affiliation:
Keywords: Breast cancer, oxidative stress, estrogen, angiogenesis, inflammation, nitric oxide, proliferation
Abstract: Nitric oxide is a pleiotropic ancestral molecule, which elicits beneficial effect in many physiological settings but is also tenaciously expressed in numerous pathological conditions, particularly breast tumors. Nitric oxide is particularly harmful in adipogenic milieu of the breast, where it initiates and promotes tumorigenesis. Epidemiological studies have associated populations at a greater risk for developing breast cancer, predominantly estrogen receptor positive tumors, to express specific polymorphic forms of endothelial nitric oxide synthase, that produce sustained low levels of nitric oxide. Low sustained nitric oxide generates oxidative stress and inflammatory conditions at susceptible sites in the heterogeneous microenvironment of the breast, where it promotes cancer related events in specific cell types. Inflammatory conditions also stimulate inducible nitric oxide synthase expression, which dependent on the microenvironment, could promote or inhibit mammary tumors. In this review we re-examine the mechanisms by which nitric oxide promotes initiation and progression of breast cancer and address some of the controversies in the field.
Export Options
About this article
Cite this article as:
Pervin Shehla, Chaudhuri Gautam and Singh Rajan, NO to Breast: When, Why and Why Not?, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232130
DOI https://dx.doi.org/10.2174/138161210790232130 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
Current Drug Metabolism Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Interaction and Cytotoxic Effects of Hydrophobized Chitosan Nanoparticles on MDA-MB-231, HeLa and Arpe-19 Cell Lines
Current Topics in Medicinal Chemistry Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Perspectives on Tuberculosis Pathogenesis and Discovery of Anti- Tubercular Drugs
Current Medicinal Chemistry Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Editorial [Hot topic: Breast Cancer: Novel Therapeutic Targets (Guest Editor: George W. Yip)]
Recent Patents on Anti-Cancer Drug Discovery The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Controlling Protein Transport by Small Molecules
Current Drug Targets Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
Current Pharmaceutical Design Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Editorial [Hot topic: Microbiota, Innate Immune and Anti-Inflammation (Guest Editor: Jun Sun)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Targeting Histone Onco- Modifications Using Plant-Derived Products
Current Drug Targets Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics